Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
141.3 USD | +1.13% | +5.95% | +34.28% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company appears highly valued given the size of its balance sheet.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+34.28% | 12.26B | B- | ||
+13.91% | 81.84B | C+ | ||
-31.26% | 70.69B | B- | ||
+9.37% | 29.03B | C+ | ||
-12.22% | 16.97B | B | ||
-0.36% | 16.83B | A- | ||
-1.73% | 15.28B | A- | ||
+5.90% | 12.41B | A- | ||
-4.20% | 11.86B | A- | ||
-31.05% | 11.83B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DVA Stock
- Ratings DaVita Inc.